Skip Navigation

This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Morice, P.
Right arrow Articles by Michel, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morice, P.
Right arrow Articles by Michel, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol 13, 660-663, Copyright © 1998 by Oxford University Press


ARTICLES

Fertility results after ovarian transposition for pelvic malignancies treated by external irradiation or brachytherapy

P Morice, R Thiam-Ba, D Castaigne, C Haie-Meder, A Gerbaulet, P Pautier, P Duvillard and G Michel
Service de Chirurgie Gynecologique, Institut Gustave Roussy, Villejuif, France.

The aim of this study was to assess the fertility outcome after ovarian transposition with uterine conservation and pelvic irradiation therapy for pelvic cancer. A total of 37 consecutive cases were reviewed. Of these, 27 patients were treated for a clear cell adenocarcinoma of the vagina and/or the cervix (group 1), nine for an ovarian pure dysgerminoma and one for a para-uterine soft tissue sarcoma (group 2). The pregnancy rate was 15% (4/27) in group 1 and 80% (8/10) in group 2 (P=0.01). A total of 18 pregnancies was observed in 12 patients. Of these, 16 pregnancies were obtained spontaneously and two after in- vitro fertilization. Of the spontaneous pregnancies, 12 (75%) were observed with ovaries still in the abdominal cavity (not repositioned). These results show that the prognosis for fertility is excellent after ovarian transposition and irradiation in patients with morphologically normal genital tracts (group 2). The prognosis is not as good for patients treated for a clear cell adenocarcinoma of the vagina and/or the cervix who may have morphological and/ or functional anomalies of the genital tract, following exposure to diethylstilboestrol and brachytherapy (group 1). Furthermore, these results show that repositioning of the ovary is not essential to achieve pregnancy.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
The Obstetrician and GynaecologistHome page
P. Ellis and T. Mould
Fertility-saving treatment in gynaecological oncology
Obstet Gynaecol (Lond), October 1, 2009; 11(4): 239 - 244.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. J. Lee, L. R. Schover, A. H. Partridge, P. Patrizio, W. H. Wallace, K. Hagerty, L. N. Beck, L. V. Brennan, and K. Oktay
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
J. Clin. Oncol., June 20, 2006; 24(18): 2917 - 2931.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. M. Leitao Jr and D. S. Chi
Fertility-Sparing Options for Patients with Gynecologic Malignancies
Oncologist, September 1, 2005; 10(8): 613 - 622.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
M. Sonmezer and K. Oktay
Fertility preservation in female patients
Hum. Reprod. Update, May 1, 2004; 10(3): 251 - 266.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.